Cabaletta Bio Extends Cash Runway as Drug Trials Advance

PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) extended its operating cash runway into early 2028 after receiving approximately $115 million from warrant exercises during the third quarter…

Timothy Alexander

Original contributor via Mychesco

| November 11, 2026 | 1 min read | Updated Nov 12, 5:00 AM

Cabaletta Bio Extends Cash Runway as Drug Trials Advance — Image supplied with the source report: Mychesco.

PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) extended its operating cash runway into early 2028 after receiving approximately $115 million from warrant exercises during the third quarter…

PHILADELPHIA, PA — Cabaletta Bio Inc. (Nasdaq: CABA) extended its operating cash runway into early 2028 after receiving approximately $115 million from warrant exercises during the third quarter of 2026, …

Source disclosure

This is a source-linked briefing. Read the original report from Mychesco .